Recent Posts
- Maryland Stem Cell Research Commission Announces $4 Million in Grants to Drive Stem Cell Innovations
- Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical Advisory Board
- Secretome Therapeutics Appoints Deepa Prasad as Chief Financial Officer
- Neoprogen is now Secretome Therapeutics, in alignment with the company’s focus in revolutionizing cell therapy via neonatal cardiac progenitor cells (nCPCs) and their respective secretomes
- NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure